Toll-like Receptor (TLR) Agonist

Toll-like Receptor (TLR) Agonists (244):

Cat. No.	Nom du produit	Effet	Pureté

HY-153900

TLR8 agonist 6	Agonist
TLR8 agonist 6 (Compound A) is a TLR8 agonist, with an EC₅₀ of 0.052 μM. TLR8 agonist 6 induces IL-12p40 production in human PBMC (EC₅₀: 0.031 μM). TLR8 agonist 6 can be used in the research of virus resistance, infection resistance, autoimmunity, tumor, etc.

HY-B0180C

Imiquimod dihydrochloride	Agonist
Imiquimod (R 837) dihydrochloride, an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.

HY-161630

TLR8 agonist 8	Agonist
TLR8 agonist 8 (Compound II-72) is an agonist for Toll-like receptor 8 (TLR8) with EC₅₀ of 0.25-1 μM. TLR8 agonist 8 is stable in human and murine plasma, induces secretion of cytokines TNFα, with EC₅₀ <1 μM. TLR8 agonist 8 exhibits antitumor activity in MC38-HER2 xenograft mouse model with a tumor growth inhibition (TGI) rate of 89%.

HY-159671A

3D-Monophosphoryl Lipid (14) triethylamine	Agonist
3D-Monophosphoryl Lipid (14) (3D-Monophosphoryl Lipid (14)) triethylamine is a TLR4 agonist that can be used as a vaccine adjuvant to enhance the immunogenicity of vaccines.

HY-183301

TLR2/1 agonist-1	Agonist
TLR2/1 agonist-1 is a selective agonist of the TLR2/1 heterodimer. TLR2/1 agonist-1 acts as a hematopoietic recovery inducer to accelerate the recovery of peripheral blood cells. TLR2/1 agonist-1 serves as a G-CSF production inducer to increase serum G-CSF levels. TLR2/1 agonist-1 exhibits radioprotective effects in mice exposed to radiation. TLR2/1 agonist-1 can be used in studies related to acute radiation syndrome.

HY-181916

BXY-14	Agonist
BXY-14 is a TLR2 agonist and vaccine adjuvant. BXY-14 significantly downregulates the expression of intratumoral PD-L1 in mouse models. BXY-14 acts as a vaccine adjuvant to induce antibody responses. BXY-14 exhibits synergistic efficacy when combined with the anti-PD-L1 monoclonal antibody Atezolizumab (HY-P9904) in mouse models of melanoma, and prolongs overall survival. BXY-14 is applicable to research related to melanoma.

HY-159672B

3D-Monophosphoryl Lipid (12,16) triethylamine	Agonist
3D-Monophosphoryl Lipid (12,16) (3D-MPL (12,16)) triethylamine is a TLR4 agonist that can be used as a vaccine adjuvant to enhance the immunogenicity of vaccines.

HY-149650A

TLR4 agonist-1 TEA	Agonist
TLR4 agonist-1 (TEA) (compound 17a) is a potent agonist of Toll-like Receptor 4 (TLR4), and induces the generation of MIP-1β in RAW 264.7 and MM6 cells.

HY-159100

PVP-037	Agonist
PVP-037 is a potent TLR7 and TLR8 agonist adjuvant. PVP-037 shows broad innate immune activation and enhances vaccine immune responses .

HY-155801

CRX 527	Agonist
CRX 527 is a TLR4 agonist. CRX 527 activates the MyD88-dependent, TRIF-dependent, and TRAF6/NF-κB signaling pathways downstream of TLR4, mimics lipid A, and regulates antigen processing and presentation by dendritic cells. CRX 527 stimulates innate immune responses and enhances vaccine efficacy. CRX 527 maintains the structural integrity of hematopoietic tissues, spleen and intestine, alleviates radiation-induced damage, preserves intestinal homeostasis, and inhibits apoptosis, inflammatory responses, oxidative stress and DNA damage. CRX 527 can be used in the research of acute radiation syndrome, melanoma, HPV-related tumors and intracerebral hemorrhage.

HY-177617A

Bazlitoran sodium	Agonist
Bazlitoran sodium (IMO-8400 sodium) is an oligonucleotide-based TLR7/8/9 antagonist. Bazlitoran sodium blocks the activation of Toll-like receptors 7, 8, and 9. Bazlitoran sodium inhibits cytokine responses mediated by Toll-like receptors 7, 8, and 9. Bazlitoran sodium is associated with injection site reactions. Bazlitoran sodium improves moderate-to-severe plaque psoriasis.

HY-177623

CpG-ODN c41	Agonist
CpG-ODN c41, an oligonucleotide, is an antagonist of TLR9.

HY-P1405

Pam3CSK4-Biotin	Agonist
Pam3CSK4-Biotin is biotinylated Pam3CSK4. Pam3CSK4-Biotin is a Toll-like receptor 1/2 (TLR1/2) agonist.

HY-177638B

ISIS 1082 sodium scrambled negative control	Agonist
ISIS 1082 sodium scrambled negative control is the sequence scrambled negative control of ISIS 1082 sodium.

HY-177665

Sitmutolimod	Agonist
Sitmutolimod, a CpG oligonucleotide, is a Toll-like receptor agonist with antineoplastic activity.

HY-153070

TLR7 agonist 5	Agonist
TLR7 agonist 5 (compound IIb-11) is an TLR7 agonist with an EC₅₀ value of ~4 nM.

HY-159751

HS101	Agonist
HS101 is a vaccine adjuvant and a key component in vaccines. Adjuvants can be divided into immunostimulants and delivery systems. Adjuvants can not only enhance the intensity and durability of immune responses, but also affect the type of immune responses. On the one hand, immunostimulants promote the production of antigen signals and co-stimulatory signals by targeting Toll-like receptors (TLRs) and other pattern recognition receptors (PRRs), leading to the maturation and activation of antigen presenting cells (APCs), thereby enhancing adaptive immune responses; on the other hand, delivery systems are carrier materials that promote antigen delivery by prolonging the bioavailability of loaded antigens and targeting antigens to lymph nodes or APCs. Several common adjuvants include: saponins, TLRs agonists, polysaccharides, nanoparticles, cytokines, and mucosal adjuvants.

HY-N6612A

D-Glucuronic acid sodium salt monohydrate	Agonist	98.0%
D-Glucuronic acid sodium salt monohydrate is a major component of many anti-inflammatory proteoglycans, which can promote embryonic development and inhibit cell aggregation. After being metabolized into ethyl glucuronide (HY-113093), D-Glucuronic acid sodium salt monohydrate activates Toll-like receptor 4 (TLR4), causing pain. D-Glucuronic acid sodium salt monohydrate and its derivative glucurono-lactone can serve as liver detoxifiers, and its derivatives also possess anti-tumor activity.

HY-164386

Defoslimod	Agonist
Defoslimod (OM 174) is an agonist for TLR4 receptor and acts as an immunomodulator. Defoslimod activates macrophages and dendritic cells, induces cytokines secretion, and exhibits antitumor efficacy in rats.

HY-150219

ODN M326	Agonist
ODN M326 (CpG-ODN M326) is a potent TLR9 agonist. ODN M326 induces the production of TNF. ODN M326 can be used as a vaccine adjuvant.

Nom
Email *

	Sorry, but the email address you supplied was invalid.